194 Results for "

refractory

" in MedChemExpress (MCE) Product Catalog:
Products (194)

194 Results for "refractory" in MCE Product Catalog:

89
89 Publications Verification
Art. -Nr.: HY-10224A
CAS. Nr.: 960055-56-5
Reinheit:  98.67%
Synonyms: LBH589 lactate; NVP-LBH589 lactate
Target:  

HDAC HIV Autophagy Apoptosis

Forschungsgebiete:  

Infection Cancer

Panobinostat lactate is a potent and orally active non-selective HDAC inhibitor. Panobinostat lactate has antineoplastic activities. Panobinostat lactate effectively disrupts HIV latency. Panobinostat lactate induces cell apoptosis and autophagy. Panobinostat lactate can be used for the study of refractory or relapsed multiple myeloma .
loading...
    loading...
89
89 Publications Verification
Art. -Nr.: HY-10224
CAS. Nr.: 404950-80-7
Reinheit:  99.37%
Synonyms: LBH589; NVP-LBH589
Target:  

HDAC Autophagy HIV Apoptosis

Forschungsgebiete:  

Cancer

Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities . Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells . Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma .
loading...
    loading...
52
52 Cited Publications
Art. -Nr.: HY-15676
CAS. Nr.: 1229705-06-9
Reinheit:  99.93%
Synonyms: RG7388
Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors .
loading...
    loading...
33
33 Cited Publications
Art. -Nr.: HY-101563
CAS. Nr.: 1616392-22-3
Reinheit:  99.51%
Synonyms: EPZ015938
GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma .
loading...
    loading...
28
28 Cited Publications
Art. -Nr.: HY-112037
CAS. Nr.: 1570496-34-2
Reinheit:  99.68%
Synonyms: IACS-10759
IACS-010759 is an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 has the potential for relapsed/refractory AML and solid tumors research .
loading...
    loading...
28
28 Cited Publications
Art. -Nr.: HY-112037A
CAS. Nr.: 1807523-99-4
Reinheit:  99.58%
Synonyms: IACS-10759 hydrochloride
IACS-010759 hydrochlorideis an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 hydrochlorideinhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 hydrochloride has the potential for relapsed/refractory AML and solid tumors research .
loading...
    loading...
24
24 Cited Publications
Art. -Nr.: HY-13032B
CAS. Nr.: 1895049-20-3
Reinheit:  97.04%
Synonyms: GSK 525762C; I-BET 762 besylate
Forschungsgebiete:  

Cancer

Molibresib besylate (GSK 525762C; I-BET 762 besylate) is an orally active pan-BET inhibitor that targets and binds to BRD2, BRD3, BRD4 and BRDT. By competitively occupying acetylated lysine binding sites, Molibresib besylate disrupts the interaction between BET proteins and chromatin, thereby effectively inhibiting MYC expression and target gene transcription. Molibresib besylate exhibits broad antiproliferative activity, which not only inhibits cancer cell growth and induces growth arrest, but also downregulates mitosis-related genes and upregulates the level of p-ERK1/2. When combined with MEK inhibitors, Molibresib besylate shows a significant synergistic effect, reduces tumor burden in mouse models of leukemia, modulates the immune microenvironment and prolongs survival. Molibresib besylate is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer and various advanced refractory solid tumors .
loading...
    loading...
10
10 Cited Publications
Art. -Nr.: HY-144858
CAS. Nr.: 2411748-50-8
Reinheit:  99.11%
Forschungsgebiete:  

Cancer

EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 (IC50=18 nM in SETD2 biochemical assay; IC50=34 nM in cellular assay). EZM0414 can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma .
loading...
    loading...
10
10 Cited Publications
Art. -Nr.: HY-10446
CAS. Nr.: 146464-95-1
Reinheit:  99.22%
Target:  

Antifolate Apoptosis

Forschungsgebiete:  

Cancer

Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a Ki of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment . Pralatrexate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
10
10 Cited Publications
Art. -Nr.: HY-136328
CAS. Nr.: 2411759-92-5
Reinheit:  97.20%
Synonyms: SETD2-IN-1 TFA
Forschungsgebiete:  

Cancer

EZM0414 (SETD2-IN-1) TFA is the TFA salt form of EZM0414 (HY-144858). EZM0414 TFA is a potent, selective, orally active inhibitor of SETD2 (IC50=18 nM in SETD2 biochemical assay; IC50=34 nM in cellular assay). EZM0414 TFA can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma .
loading...
    loading...
7
7 Cited Publications
Art. -Nr.: HY-109117
CAS. Nr.: 1431304-21-0
Reinheit:  99.82%
Synonyms: ORY-1001
Forschungsgebiete:  

Cancer

Iadademstat (ORY-1001) is a highly potent, orally active and selective LSD1 (KDM1A) inhibitor with antileukemic activity. Iadademstat can be used for relapsed or refractory acute myeloid leukemia research .
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-109108
CAS. Nr.: 1809336-39-7
Reinheit:  99.68%
Synonyms: DS-3201
Forschungsgebiete:  

Cancer

Valemetostat (DS-3201), a first-in-class EZH1/2 dual inhibitor with IC50 values <10 nM. Valemetostat can be used for the research of relapsed/refractory peripheral T-cell lymphoma .
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-109108A
CAS. Nr.: 1809336-93-3
Reinheit:  99.84%
Synonyms: DS-3201 tosylate
Forschungsgebiete:  

Cancer

Valemetostat (DS-3201) tosylate, a first-in-class EZH1/2 dual inhibitor with IC50 values <10 nM. Valemetostat tosylate can be used for the research of relapsed/refractory peripheral T-cell lymphoma .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-109068
CAS. Nr.: 1426698-88-5
Reinheit:  99.20%
Synonyms: INCB050465; IBI-376
Target:  

PI3K

Forschungsgebiete:  

Cancer

Parsaclisib (INCB050465) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC50 of 1 nM at 1 mM ATP. Parsaclisib shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib can be used for the research of relapsed or refractory B-cell malignancies .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-109068A
CAS. Nr.: 1995889-48-9
Synonyms: INCB050465 hydrochloride; IBI-376 hydrochloride
Target:  

PI3K

Forschungsgebiete:  

Cancer

Parsaclisib hydrochloride (INCB050465 hydrochloride) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC50 of 1 nM at 1 mM ATP. Parsaclisib hydrochloride shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib hydrochloride can be used for the research of relapsed or refractory B-cell malignancies .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-B0984
CAS. Nr.: 13636-18-5
Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-B0984A
CAS. Nr.: 13042-18-7
Fendiline, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-P9980
CAS. Nr.: 2061894-48-0
Synonyms: GSK2857914

Forschungsgebiete:  

Cancer

Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma .
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-P99100
CAS. Nr.: 2556646-63-8
Synonyms: CTL-002

Forschungsgebiete:  

Cancer

Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-P99033
CAS. Nr.: 1905409-39-3
Synonyms: BTCT-4465A; RG-7828; RO7030816

Target:  

CD20 CD3

Forschungsgebiete:  

Inflammation/Immunology Cancer

Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
loading...
    loading...